ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Ascendis Pharma A/S (ASND) stock surged +4.03%, trading at $173.50 on NASDAQ, up from the previous close of $166.78. The stock opened at $169.61, fluctuating between $167.52 and $176.89 in the recent session.
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Employees | 1017 |
Beta | 0.36 |
Sales or Revenue | $266.72M |
5Y Sales Change% | 17.399% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |